MedTrace Logo

Clinical Potassium Pilot Study

NCT04251468 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-09-16

No results posted yet for this study

Summary

In this pilot study, 30 prevalent hemodialysis patients will undergo three regular hemodialysis sessions during which various potassium assessments will be performed. Pre- (t1) and post-dialysis (t2) plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes. These values will be correlated to K+ determine in saliva probes (K+Sa) using genetically encoded potassium ion indicators (GEPIIs). Additionally, continuous ECG will be recorded during each hemodialysis treatment and potassium assessment (K+ECG) will be performed upon ECG-based parameters and correlated to K+Pl.

Conditions

  • Hyperkalemia

Interventions

DEVICE

GEPII

Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)

DEVICE

Ion-selective electrodes

Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.

Sponsors & Collaborators

  • NGFI Next Generation Fluorescence Imaging GmbH

    collaborator UNKNOWN

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Alexander H. Kirsch, MD · Medical University of Graz

  • Andras T. Deak, MD · Medical University of Graz

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-29
Primary Completion
2020-09-09
Completion
2020-09-09

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04251468 on ClinicalTrials.gov